Andrew B. Lassman, MD
Appointments
Phone Appointments
myColumbiaDoctors
For existing patients, login to make an appointment, view documentation or contact your care provider.
Credentials & Experience
Board Certifications
- Neurology
Clinical Expertise
- Neuro-Oncology
- Cancer Care
- Brain & Spinal Tumors
- Acoustic Neuroma
- Astrocytoma
- Anaplastic Astrocytoma
- Brain Tumor
- Brain Metastases
- Brain Stem Glioma
- Brain Cancer
- Carcinomatous meningitis
- Chordoma
- Choroid Plexus Papilloma
- Choroid Plexus Carcinoma
- Ependymoma
- Gliomas
- Glioblastoma
- Glioblastoma Multiforme
- Hemangioblastoma
- Leptomeningeal metastases
- Medulloblastoma
- Meningioma
- Metastatic Cancer
- Mixed Glioma
- Neurofibromatosis
- Oligodendroglioma
- Oligoastrocytoma
- Second Opinion
- Spinal Cord Tumor
- Spinal Tumors
Education & Training
- MD, Columbia University College of Physicians and Surgeons
- Internship: Mount Sinai Hospital
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: Memorial Sloan-Kettering Cancer Center
Honors & Awards
- Neurology Resident Teaching Award, Memorial Sloan-Kettering Cancer Center/Weill Medical College of Cornell University
- Preuss Award in Neuro-Oncology, American Academy of Neurology
- Boyer Clinical Research Award, Memorial Sloan-Kettering Cancer Center
- Gary Lichtenstein Humanitarian Award, Voices Against Brain Cancer
About Andrew Lassman
Andrew B. Lassman, MD, is the John Harris Associate Professor of Neurology and the Chief of Neuro-oncology at Columbia University. After earning BS and MS degrees in Molecular Biophysics and Biochemistry as part of a combined 4-year program at Yale University, he received his MD from Columbia University College of Physicians and Surgeons. Dr. Lassman subsequently completed his residency at the Neurological Institute of NewYork-Presbyterian Hospital/Columbia University Medical Center, and fellowship in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center, where he then joined the faculty and served as fellowship director.
In November 2011, Dr. Lassman became Chief of Neuro-Oncology at Columbia University Medical Center, and also serves as the Medical Director for the Clinical Protocol Data Management Office of the Herbert Irving Comprehensive Cancer Center.
Dr. Lassman received the Preuss Award in Neuro-Oncology from the American Academy of Neurology, the Boyer Clinical Research Award from Memorial Sloan-Kettering Cancer Center, and the Gary Lichtenstein Humanitarian Award from Voices Against Brain Cancer. His clinical practice is limited to central nervous system tumors and metastases.
Academic Titles
- John Harris Associate Professor of Neurology
Administrative Positions
- Chief, Division of Neuro-Oncology
- Co-Director, Brain Tumor Center
Committee/Societies/Council Memberships
American Medical Association, Member
American Academy of Neurology, Member
Society for Neuro-Oncology, Member
American Society of Clinical Oncology, Member
Radiation Therapy Oncology Group, Brain Committee
Society for Neuro-Oncology, Annual Meeting, Abstract Review Committee
NIH Common Terminology Criteria for Adverse Events (CTCAE) Revision Committee
United Council for Neurologic Subspecialties Board, Neuro-Oncology Representative
Voices Against Brain Cancer Medical Advisory Board
American Society of Clinical Oncology, Scientific Program Committee, CNS Track
American College of Radiation Oncology, Scientific Program Committee
Hospital Affiliations
- NewYork-Presbyterian/Columbia
Gender
- Male
Insurance Accepted
Aetna
- EPO
- HMO
- Medicare Managed Care
- NY Signature
- POS
- PPO
- Signature Administrators
- Student Health
Affinity
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Amida Care
- Special Needs Plan
Cigna
- EPO
- Great West
- HMO
- POS
- PPO
Emblem/GHI
- HMO
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield
- Blue Priority
- EPO
- HMO
- Medicare (Mediblue)
- NYP Employee Plan
- Pathway (Exchange)
- POS
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare
- MagnaCare
Multiplan
- Multiplan
Oxford Health Plans
- Freedom
- Liberty
- Medicare Managed Care
POMCO
- POMCO
UnitedHealthcare
- Columbia University Employee Plan
- Compass (Exchange)
- EPO
- Essential Plan
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
WellCare
- Medicaid Managed Care
- Medicare Managed Care
*Please contact the provider’s office directly to verify that your particular insurance is accepted.
Contact & Locations
New York, New York 10032
Research
Dr. Lassman's research interests focus on translational clinical trials for brain tumors with molecular correlative analyses to understand the reasons for treatment success or failure, and to refine treatment paradigms.
Research Interests
- Translational clinical trials for brain tumors
- Brain and leptomeningeal metastases
Clinical Trials
Multiple clinical trials for patients with brain tumors metastases
Grants
SERVICE AGREEMENT: A TWO-PART, PHASE I/IIA DOSE-ESCALATION CLINICAL TRAIL TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN (P&S Industry Clinical Trial)
Dec 6 2017 - Dec 6 2022
A TWO-PART, PHASE I/IIA DOSE-ESCALATION STUDY TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN RECURRENT GBM SUBJECTS. (P&S Industry Clinical Trial)
Nov 29 2017 - Nov 29 2022
A STUDY OF RADIOLOGICALLY EVIDENT TREATMENT EFFECTS IN SUBJECTS WITH GLIOBLASTOMA MULTIFORME (GBM) (P&S Industry Clinical Trial)
May 15 2017 - May 15 2022
A PHASE 2, MULTICENTER STUDY OF TESEVATINIB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
Apr 18 2017 - Apr 18 2022
PHASE I/II DOSE ESCALATION TRIAL TO ASSESS SAFETY OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES IN HER2 POSITIVE BREAST CANCER (P&S Industry Clinical Trial)
Feb 4 2015 - Feb 4 2020
PHASE II TRIAL OF VELCADE? (BORTEZOMIB) IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Dec 11 2014 - Dec 11 2019
COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)
Aug 1 2014 - Jul 31 2019
A PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH RECURRENT SOLID TUMOR BRAIN METASTASES WHO HAVE FAILED WHOLE BRAIN RADIATION THERAPY (P&S Industry Clinical Trial)
Jul 18 2014 - Jul 18 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
A PHASE II, TWO TIER STUDY EVALUATING THE EFFICACY AND SAFETY OF SELINEXOR (KPT 330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA AFTER FAILURE OF RADIATION THERAPY AND TEMOZOLOMIDE (P&S Industry Clinical Trial)
Jun 20 2014 - Jun 20 2019
A PHASE IB/II, OPEN LABEL, MULITCENTER STUDY OF INC280 IN COMBINATION WITH BUPARLISIB IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
May 14 2014 - May 14 2019
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL LDE225 VERSUS TEMOZOLOMIDE IN PATIENTS WITH HH-PATHWAY ACTIVATED RELAPSED MEDULLOBLASTOMA (P&S Industry Clinical Trial)
Oct 2 2013 - Oct 2 2018
A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ABT-414 IN COMBINATION WITH RADIATION PLUS TEMOZOLOMIDE OR TEMOZOLOMIDE ALONE (P&S Industry Clinical Trial)
Aug 13 2013 - Aug 13 2018
AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PLX3397 IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (P&S Industry Clinical Trial)
Jul 26 2013 - Jul 26 2018
IDENTIFYING LEPTOMENINGEAL METASTASIS FROM BREAST CANCER UTILIZING A NOVEL IMMUNOCYTOCHEMICAL MICROFLUIDIC DEVICE (Federal Gov)
Jul 15 2016 - Jun 30 2018
PHASE II STUDY OF AMG 386 WITH AND WITHOUT BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
Apr 23 2013 - Apr 23 2018
PILOT STUDY OF EGFR INHIBITION USING HIGH DOSE ADMINISTRATION OF ERLOTINIB WEEKLY FOR RECURRENT MALIGNANT GLIOMAS WITH EGFR VARIANT III MUTATION - PILOT STUDY OF EGFR INHIBITION FOR GMB (P&S Industry Clinical Trial)
Jan 10 2013 - Jan 10 2018
CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION (INTELLANCE 1) (RTOG 3508) (Private)
Sep 1 2015 - Aug 31 2016
A PHASE 2 STUDY OF MEDI-575 IN ADULT SUBJECTS WITH RECURRENTGLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Jan 5 2011 - Jan 5 2016
PHASE II CLINICAL TRIAL OF PERIFOSINE + TEMSIROLIMUS FOR RECURRENT GLIOBLASTOMA WITH TISSUE AND IMAGING CORRELATES OF RESPONSE (Private)
Jan 1 2013 - Dec 31 2015
COLUMBIA UNIVERSITY MEDICAL CENTER MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM (MB-CCOP) (Federal Gov)
Aug 6 2012 - May 31 2015
RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)
Jan 1 2009 - Dec 31 2014
PULSATILE KINASE INHIBITOR THERAPY FOR MALIGNANT GILOMA: PROOF OF CONCEPT CLINICAL TRIAL (Private)
Jun 1 2013 - May 31 2014
For a complete list of publications, please visit PubMed.gov